Wednesday, February 18, 2009
FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
THOUSAND OAKS, Calif. – Feb. 18 – Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Amgen’s submission and filed a Biologics License Application (BLA) for denosumab, an investigational RANK Ligand inhibitor. The indications for which Amgen is seeking FDA approval are treatment and prevention of postmenopausal osteoporosis (PMO) in women and treatment and prevention of bone loss in patients undergoing hormone ablation therapy for either prostate or breast cancer.
Read the rest of this entryPosted in Press Releases, Pipeline News
Wednesday, February 11, 2009
Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., Feb. 11 and OSAKA, Japan – Feb. 12, 2009 – Amgen (Nasdaq: AMGN), Millennium: The Takeda Oncology Company, and its parent company Takeda Pharmaceutical Company Limited (TSE:4052) today announced the Independent Data Monitoring Committee (DMC) for the MONET1 trial has recommended the trial resume enrollment of patients with non-squamous non-small cell lung cancer (NSCLC) following a three-month enrollment suspension. MONET1 is a Phase 3 study evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced NSCLC. Motesanib is part of a co-development program between Amgen, Millennium and Takeda.
Read the rest of this entryPosted in Press Releases
Friday, February 06, 2009
Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
First and Only Approved Platelet Producer in Europe Represents New Treatment Approach for Serious Chronic Autoimmune Disorder
ZUG, Switzerland – Feb. 6 – Amgen (Nasdaq: AMGN) today announced that the European Commission (EC) has granted marketing authorisation for Nplate(R) (romiplostim) for the treatment of splenectomised adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Nplate may be considered as second line treatment for adult non-splenectomised ITP patients where surgery is contra-indicated.
Read the rest of this entryPosted in Press Releases, Product News
Monday, January 26, 2009
Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
Full Year 2008 Revenue Increased 2 Percent to $15.0 Billion; Fourth Quarter 2008 Revenue Flat at $3.75 Billion
Full Year 2008 GAAP Earnings Per Share Increased 38 Percent to $3.90; Fourth Quarter 2008 GAAP Earnings Per Share Increased 20 Percent to $0.91
2009 Total Revenue Expected to be in the Range of $14.8 to $15.2 Billion
2009 Adjusted Earnings Per Share Expected to be in the Range of $4.55 to $4.75
THOUSAND OAKS, Calif. – Jan. 26 – Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.06 for the fourth quarter of 2008, an increase of 6 percent compared to $1.00 for the fourth quarter of 2007. Adjusted net income, excluding stock option expense and certain other expenses, increased 3 percent to $1,124 million in the fourth quarter of 2008 compared to $1,088 million in the fourth quarter of 2007. Stock option expense on a per share basis totaled 2 cents and 3 cents in the fourth quarter of 2008 and the fourth quarter of 2007, respectively.
Read the rest of this entryPosted in Press Releases
Thursday, January 22, 2009
Amgen's Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
THOUSAND OAKS, Calif. – Jan. 22 – In an ongoing effort to raise awareness of the comprehensive continuum of resources available to cancer patients and their caregivers—from prevention to education, patient care to advocacy and financial support --Amgen’s Breakaway from Cancer(TM) initiative has expanded its charitable partners to now include the National Coalition for Cancer Survivorship, Patient Advocate Foundation, Prevent Cancer Foundation and The Wellness Community.
Read the rest of this entryPosted in Philanthropy
Add Amgen RSS
Feeds to iGoogle
Subscribe to
Amgen RSS Feeds
Archives
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
Amgen News (all)